Flutox (Cloperastine)

Quick links

Choose a section

Quick links to important sections

Advertisements

Flutox (Cloperastine)

Advertisements
Advertisements

Method of action: Cough And Cold Preparations

Treatment option:

Advertisements

Overview of Flutox (Cloperastine)

Flutox is a medicine containing the single active ingredient Cloperastine, and its primary function is to act as a centrally acting antitussive designed to calm the impulse to cough. This medication is classified chemically as a synthetic Phenylpiperidine derivative and is specifically engineered to relieve non-productive coughing.


Quick Facts: Cloperastine Identity

Property Description
Active ingredient Cloperastine (as Fendizoate or Hydrochloride salt)
Form Oral solution (syrup), Tablets
Pharmacological class Non-opioid Antitussive (Cough Suppressant)
Common use Symptomatic relief of dry, irritative cough
Origin Synthetic; Phenylpiperidine derivative

What Type of Medicine is Flutox (Cloperastine)?

Cloperastine is classified as a non-opioid antitussive that suppresses the cough reflex through a direct action on the cough center located in the brainstem. The medication moderates cough reflex activity through this central effect without exhibiting narcotic properties. Importantly, because Cloperastine is a non-narcotic substance, its use avoids the dependence risk associated with opioid-based cough suppressants. Furthermore, Cloperastine possesses a mild secondary antihistamine action, although its main therapeutic role is dedicated to cough suppression.


Composition and Available Forms of Cloperastine

Cloperastine is a monocomponent preparation, meaning it is the sole pharmaceutical compound responsible for the therapeutic effect, typically utilized as a salt such as Cloperastine Fendizoate or Cloperastine Hydrochloride. The Fendizoate salt, often used in the liquid formulation, provides a prolonged action. For patients, Flutox is commonly supplied for oral route of administration in two main dosage forms: a liquid oral solution (syrup) and solid tablets. The liquid form, prepared with an aqueous base, allows for flexible ingestion and is particularly suitable for pediatric use.


What is the General Purpose of Flutox?

The general purpose of Flutox is to provide effective symptomatic relief by calming the cough impulse caused by irritation. By reducing the central signal that triggers the spasm, the medicine aims to alleviate the distress and fatigue associated with persistent, dry, irritating, and non-productive coughs that do not contribute to clearing the respiratory tract. Its focused, central action makes it suitable for coughs where the primary need is to quieten the reflex itself.

Advertisements

What side effects are possible with Flutox (Cloperastine)?

Possible side effects and safety information

The official safety information for Cloperastine documents adverse reactions primarily associated with its action on the central nervous system (CNS) and mild anticholinergic properties. These reactions are formally organized into frequency categories and System-Organ Classes (SOC) by regulatory agencies.

Adverse Reaction Frequencies

Side effects are classified based on the documented probability of occurrence:

  • Common: Reactions that are most frequently reported include drowsiness (somnolence), dizziness, dry mouth, constipation, nausea, and fatigue.
  • Rare: Documented as occurring infrequently, examples include urinary retention and certain hypersensitivity reactions.
  • Very Rare: These include severe but exceptionally infrequent events such as angioedema, hypotension, and tachycardia.

Safety Considerations and Restrictions

The regulatory label outlines specific safety limitations. Due to the potential for drowsiness, caution is formally advised regarding activities like driving or operating machinery. Concurrent use with other CNS depressants, including alcohol, may enhance sedative effects and is an official restriction.

Specific cautions are noted for certain populations and pre-existing conditions:

  • Population Notes: Caution is recommended in patients with existing hepatic or renal impairment due to the role of these organs in drug elimination.
  • Anticholinergic Effects: Due to the medicine's mild anticholinergic activity, caution is advised for patients with conditions such as narrow-angle glaucoma or prostatic hypertrophy where urinary retention may be a risk.

This structure ensures clear communication of the established risks and defines the safety boundaries for the medicine’s use, based strictly on government-approved prescribing information.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Flutox (Cloperastine) strictly describes specific clinical manifestations and severe potential outcomes in the event of overdose, along with immediate actions required.


Documented Overdose Manifestations and Outcomes

Overdose may present with Central Nervous System (CNS) signs such as excitement (sobreexcitación) and can lead to difficulties with breathing. A severe potential outcome that has been documented in the regulatory profile is respiratory depression. The official prescribing information states that there is no specific antidote documented for Cloperastine overdose.

Officially Mandated Emergency Actions

In any case of suspected overdose, immediate medical help must be sought. Regulatory guidance mandates that you consult immediately with a doctor or pharmacist, and contact the local toxicology information service without delay. When seeking urgent help, you are required to state the name of the medicine and the quantity ingested.

Supportive Management

Management is primarily symptomatic and supportive. Specific procedures detailed in the official label include the potential use of gastric lavage and the correction of systemic imbalances, such as possible acidosis and electrolyte loss. Should overexcitement occur, the administration of sedative medication is described as a required management measure. No separate overdose considerations for children or the elderly are detailed in the general regulatory profile.

Advertisements

Therapeutic Uses of Flutox (Cloperastine)

Flutox (Cloperastine) is commonly used for symptomatic management in clinical settings where additional management of discomfort from an irritating cough is required. Its therapeutic indication is as a cough suppressant. It generally provides supportive therapeutic benefit in acute episodes where symptoms that create noticeable physiological strain cause distress.

This medication is applied in contexts where a cough is defined as non-productive—meaning it is dry and lacks phlegm or mucus, and helps address symptom clusters associated with airway irritation. This makes it relevant for managing the dry cough symptoms often seen in conditions involving inflammatory or irritative processes, such as the common cold or acute bronchitis.

It offers symptomatic relief that helps patients cope more steadily during difficult episodes by easing the distress caused by frequent coughing. This may contribute to easing the impact of symptoms on routine activities and general comfort, especially regarding sleep.


Quick Fact: Relief for Dry Cough Spasms

Symptom Focus Context of Use Patient Benefit Focus
Non-Productive Cough Acute Respiratory Episodes Contributes to easing the overall symptom load.
Irritating Tickle Post-Infectious States Assists with maintaining functional stability.

Regulatory References

  1. European Directorate for the Quality of Medicines & HealthCare (EDQM)
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Flutox (Cloperastine) — Official Regulatory Information


Eligibility Scope

Populations for whom use is allowed Adults, adolescents over 12 years of age, and children from 2 years of age (syrup formulation).
Populations for whom use is not recommended Use in children under 2 years is strictly contraindicated.
Populations for whom use is contraindicated Individuals with known hypersensitivity to cloperastine or antihistamine drugs; patients with hereditary fructose intolerance (syrup); and those taking MAOI antidepressants.
Age-related eligibility rules The medicine is approved for use from 2 years of age in its oral solution form, with use below this threshold being prohibited.
Condition-specific eligibility rules Use is contraindicated in patients with respiratory failure, asthmatic cough, or a productive cough (cough with phlegm).
Pregnancy and lactation eligibility status Use is contraindicated during pregnancy and breastfeeding.
Eligibility-related restrictions Use requires precaution in patients with conditions such as glaucoma, prostatic hyperplasia, arterial hypertension, or liver disease.

Eligibility Classifications (High-Level)

Eligibility severity classification Contraindicated (Prohibition); Precaution/Caution (Conditional Use).
Regulatory basis Primarily based on European national regulatory authority documents (SmPC).
Eligibility-context constraints Includes constraints based on concurrent medication (MAOI antidepressants) and excipient intolerance.

Resulting Eligibility Structure

Official eligibility statements:

  • Use is contraindicated in children under 2 years of age.
  • The medicine is contraindicated during pregnancy and breastfeeding.
  • It is contraindicated in cases of hypersensitivity or if the patient has a productive/asthmatic cough.

Connection to the overall eligibility profile: Official regulatory documents establish mandatory non-eligibility based on specific population categories, including age, reproductive status, and the presence of severe medical conditions like respiratory failure. Further restrictions limit use, requiring precaution in patients with conditions aggravated by anticholinergic effects, such as glaucoma and prostatic hyperplasia, or certain cardiovascular disorders.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Cloperastine is primarily characterized by pharmacodynamic interactions that affect the central nervous system (CNS) and anticholinergic activity, as documented in official regulatory labeling.


Official Regulatory Interaction Constraints

Classification Interacting Substance/Class Official Regulatory Statement
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Co-administration is formally prohibited by regulatory authorities.
Pharmacodynamic Potentiation CNS Depressants (e.g., Anxiolytics, Narcotics, Hypnotics) Concomitant use may result in the enhancement of the sedative effect.
Pharmacodynamic Potentiation Anticholinergic Drugs (e.g., Tricyclic Antidepressants) Co-administration may cause a reciprocal increase in anticholinergic effects.
Drug–Substance Interaction Alcohol Co-administration may enhance the sedative effect.
Interaction Risk Expectorants and Mucolytic Drugs Combining these with the cough suppressant may risk pulmonary obstruction if bronchial secretions are high.

Population-Specific Excipient Considerations

The oral solution formulation contains sucrose, which generates interaction-related constraints for specific patient groups. This content must be taken into account for diabetic patients. Furthermore, the product is contraindicated in patients with conditions such as hereditary fructose intolerance, glucose or galactose malabsorption, or sucrase-isomaltase deficiency, due to the excipient component.

Advertisements

Mechanism of Action

How Flutox (Cloperastine) Works

Cloperastine modulates the activity of the neural network that integrates and executes the cough reflex. Its mechanism is multifaceted, combining a central effect with ancillary peripheral actions.


Central Inhibition via the Bulbar Cough Center

This domain covers Cloperastine's direct action on the brainstem, specifically the Bulbar Cough Center. The molecule acts as a ligand for the Sigma-1 Receptor (sigma1) and directly blocks GIRK Channels (G Protein-Coupled Inwardly Rectifying Potassium Channels). This molecular interference alters the membrane stability and electrical excitability of the key coordinating neurons, resulting in a change in the central neural firing threshold. This fundamental change in central activity limits the intensity and frequency of efferent signaling from the coordinating center.


Modulation of Peripheral Irritation and Airway Tone

This domain covers the ancillary effects outside of the brainstem. Cloperastine exhibits weak Antagonism at the Histamine H1 ( H1) receptor and mild Anticholinergic Antagonism at muscarinic receptors found in the airways. These actions affect the peripheral sensory input and contribute to a mild physiological relaxation of bronchial smooth muscle, influencing both the afferent and efferent signaling pathways.

Advertisements

Dosage and Administration Information

How to Use Flutox (Cloperastine)

Cloperastine is administered strictly via the oral route for the standardized, short-term management of acute cough episodes. Prescribing information defines the use of Cloperastine based on a specific, fixed-interval dosing schedule.


Standard Administration Guidelines

Guideline Entity Instruction
Route of Administration Oral
Standard Adult Dose 10 mg to 20 mg per administration
Dosing Frequency Three times daily (TID)
Timing Relative to Food May be taken independently of meals (with or without food)

Formulations and Special Use

Cloperastine is available for oral ingestion as tablets and as a liquid oral solution (syrup). The standard adult regimen requires a three-times-daily administration to maintain the antitussive effect, and this schedule is structured to be flexible with mealtimes as food does not significantly impact absorption.

In specific populations, the choice of formulation is guided by administration ease. The liquid oral solution is particularly suitable for administration to both pediatric patients and older adults who may have difficulty swallowing solid tablets. For children, labeling specifies that dosage must be carefully adjusted according to the patient's age and weight.

These instructions define a standardized protocol for use, ensuring that the medicine is administered at a consistent frequency over the short duration required for acute symptom relief.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of studies for Flutox (Cloperastine)

Evidence for Short-Term Cough Symptom Patterns

Research examining Cloperastine was evaluated in studies focusing on conditions characterized by fluctuating or episodic manifestations, such as acute or persistent cough. The primary approach used in this research involved controlled study designs, where patient-reported experiences were applied in research contexts involving unstable symptoms. These studies explored how outcomes related to physical discomfort, specifically the frequency and intensity of coughing episodes, changed over defined time intervals.

Studies monitored patient-reported outcomes describing perceived discomfort. Findings indicate patterns related to measurements of the number and perceived severity of coughs observed during the study period. Additionally, research examined temporary physiological imbalance, specifically focusing on outcomes reflecting daily functioning, such as the quality and duration of night rest when coughing was a factor. The evidence outlines observed patterns for symptoms, particularly concerning short-term symptom changes observed in the immediate period following administration.

Research in Specific Groups and Uncertainties

Studies involving Cloperastine have also been conducted in research exploring short-term symptom changes in various age groups. Data show patterns related to use in both adult populations and in children. However, comparative evidence is lacking in some areas, and evidence quality varies across studies, especially when compared to other antitussive agents studied. Findings were mixed when Cloperastine was compared against some non-opioid treatments, highlighting that data for certain groups remain insufficient for drawing comprehensive conclusions.

Research was conducted in this population, but a significant limitation is that follow-up durations were limited in most trials examining cough symptoms. This means that long-term effects are not fully established. Researchers note that evidence is limited regarding outcomes over extended periods. Findings describe group patterns, not personal outcomes, and study results apply only to the populations studied.

Key Studies & References

  1. Cloperastine (Oral Route) - MedlinePlus Drug Information
  2. Cloperastine in the treatment of cough: A review of its mechanism of action and clinical efficacy
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Flutox (Cloperastine) (FAQ)


Q: How quickly should I expect Flutox to start working for my cough?

While regulatory documents do not specify an exact minute-by-minute onset, official pharmacological data indicates the effect of a single dose typically lasts around three to four hours. This suggests that the effect occurs within this range, which aligns with the timing required to maintain consistent antitussive action.


Q: How long does the cough-suppressing effect of Flutox typically last?

According to official product information, the cough-suppressing effect of a single administration of Cloperastine generally lasts for approximately three to four hours. This duration helps guide the medicine's recommended three-times-daily use schedule.


Q: What happens if I miss a scheduled time to take Flutox?

General guidance for this type of fixed-interval medication is that if a dose is missed, you may take it as soon as you remember. However, if the time is very close to the next scheduled dose, you may skip the missed one. The purpose of this approach is to avoid taking two doses close together.


Q: Why is Flutox sometimes associated with heart palpitations?

Official safety data lists tachycardia (a fast heart rate, which can be perceived as heart palpitations) as a very rare potential side effect. This event is commonly linked in pharmacological texts to the medication’s mild anticholinergic properties, which can influence certain involuntary bodily functions.


Q: What should I do if my cough does not improve after using Flutox for a few days?

Regulatory documents advise that if the acute cough symptoms do not resolve or if they worsen after using the medication for a defined short period, such as seven days, official documents advise that discontinuing the medicine is appropriate. The guidance emphasizes that a healthcare professional should be consulted for persistent symptoms.


Q: What is the difference between Flutox and other common cough syrups?

Flutox (Cloperastine) is officially classified as a non-opioid antitussive, meaning it suppresses the cough reflex through an action on the brain's cough center without containing any narcotic or opioid substances. This classification distinguishes it from cough syrups that use opioid derivatives for their antitussive effect.


Q: Does Flutox make me feel dizzy or lightheaded?

Official safety information lists dizziness as a common side effect of Cloperastine. Furthermore, regulatory documentation notes that vertigo, which is a sensation of spinning or lightheadedness, is a reported adverse effect that users may experience.


Q: Can taking Flutox affect my blood pressure?

Official safety reports state that hypotension (low blood pressure) is documented as a very rare side effect of the medicine. Separately, official caution is advised for patients who already have arterial hypertension (high blood pressure) due to the drug's properties.


Q: Can I take Flutox if I am already taking an anti-anxiety or sleep medication?

Regulatory labeling cautions that combining Cloperastine with other Central Nervous System (CNS) depressants, such as anti-anxiety drugs (anxiolytics) and sleep medications (hypnotics), may increase the sedative effects. Official labeling indicates that such combinations should be evaluated by a healthcare professional.


Q: Are there special considerations for using Flutox in older adults?

Official guidance suggests that the dosage in older adults should be considered carefully, as individuals in this population may experience increased sensitivity to the medication. The liquid oral solution is often noted as a suitable formulation for ease of administration in this age group.


Q: Is there a maximum number of days Flutox should be used continuously?

As a symptomatic treatment for acute cough, official regulatory documents may specify a typical maximum duration of approximately seven days. It is important to note the drug is intended for short-term relief and not for chronic or long-term conditions.


Q: What is the role of the cough center in the brain, which Flutox is said to affect?

Flutox acts primarily on the Bulbar Cough Center, a coordinating area located in the brainstem (medulla oblongata). The role of this center is to process sensory input from the respiratory tract and then trigger the cough response. The medication works by modulating the activity of this network to reduce the intensity and frequency of the cough reflex.


Q: Are there different forms of Flutox (like tablets vs. syrup) and do they work the same way?

The medicine is available in two main forms: tablets and an oral solution (syrup). Both forms contain the same active ingredient and share the same core mechanism of action. Official information notes that the oral solution is specifically indicated as more suitable for populations like children and older adults who may have difficulty swallowing tablets.

Advertisements

How should Flutox (Cloperastine) be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documentation outlines specific conditions to maintain the stability and safety of Flutox (Cloperastine) syrup.

Requirement Type Official Statement
Temperature Store below 30 C.
Protection Protect from direct sunlight, heat, and water.
Child Safety Keep this medicine out of sight and reach of children.
Packaging Keep the medicine in its original packaging.
Disposal Do not dispose of via household rubbish or wastewater. Return unused or expired medicine to an authorized pharmacy collection point.

Flutox syrup has a shelf life of five years when unopened. Adherence to the stated storage conditions ensures the medicine remains effective until the expiration date. Disposal instructions mandate using designated pharmaceutical waste collection systems to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flutox (Cloperastine) found in:

A-Z Index: